The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Placebo‐controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression
Open accessAbstract
Objective: This pilot study assessed the feasibility, efficacy and safety of an individual dose‐titration approach, and of the intravenous (IV), intramuscular (IM) and subcutaneous (SC) routes for treating depression with ketamine. Method: Fifteen treatment‐refractory depressed participants received ketamine or midazolam (control treatment) in a multiple crossover, double‐blind study. Ketamine was administered by IV (n = 4), IM (n = 5) or SC (n = 6) injection. Dose titration commenced at 0.1 mg/kg, increasing by 0.1 mg/kg up to 0.5 mg/kg, given in separate treatment sessions separated by ≥1 week, with one placebo control treatment randomly inserted. Mood, psychotomimetic and hemodynamic effects were assessed and plasma ketamine concentrations assayed. Results: Twelve participants achieved response and remission criteria, achieved at doses as low as 0.1 mg/kg. All three routes of administration resulted in comparable antidepressant effects. Fewest adverse effects were noted with the SC route. Antidepressant response, adverse effects and ketamine concentrations were dose‐related. Conclusion: Antidepressant response occurred at a range of doses and at <0.5 mg/kg. The dose‐titration approach is a practical method for optimizing the efficacy – side‐effects trade‐off on an individual patient basis. This pilot study provides preliminary evidence for SC injection as a practical, feasible and efficacious treatment approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258
RetractedA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“(5) who used midazolam as an active placebo control, reporting similar subjective effects with ketamine and midazolam.”
BackgroundDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 7×
“Secondary outcomes were psychotomimetic effects, assessed using positive symptom items (hallucinations, grandiosity, suspiciousness, unusual thought content, conceptual disorganization) from the Brief Psychiatric Rating Scale (BPRS) (21), item 1 (Elevated mood) of the Young Mania Rating Scale (YMRS) (22) and the Clini…”
MethodInfluentialA Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480 · cited 1×
“Only one study (6) reported an alternative more convenient route, administering 50 mg ketamine intranasally, although with a lower response rate (44%) than other placebo-controlled studies.”
BackgroundZarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
A Multidimensional Tool to Quantify Treatment Resistance in Depression: The Maudsley Staging Method
Fekadu, A., Wooderson, S., Donaldson, C., Markopoulou, K., Masterson, B., Poon, L., & Cleare, A. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04309 · Cited by 281
Meta-analysis of the Brief Psychiatric Rating Scale factor structure.
Shafer, A. (2005) · Psychological Assessment · doi:10.1037/1040-3590.17.3.324 · Cited by 251
Valentine, G. W., Mason, G. F., Gomez, R., Fasula, M., Watzl, J., Pittman, B., Krystal, J. H., & Sanacora, G. (2011) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2010.10.009 · Cited by 204
Ghasemi, M., Kazemi, M., Yoosefi, A., Ghasemi, A., Paragomi, P., Amini, H., & Afzali, M. H. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.008 · Cited by 156
Caddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313507739 · Cited by 156
Lara, D. R., Bisol, L. W., & Munari, L. R. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000485 · Cited by 152
Pilot dose–response trial of i.v. ketamine in treatment-resistant depression
Lai, R., Katalinic, N., Glue, P., Somogyi, A. A., Mitchell, P. B., Leyden, J., Harper, S., & Loo, C. K. A. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.922697 · Cited by 119
Self-citationBall, D. M., Glue, P., Wilson, S. J., & Nutt, D. (1991) · Psychopharmacology · doi:10.1007/bf02244431 · Cited by 90
Self-citationAcute Antidepressant Effects of Intramuscular Versus Intravenous Ketamine
Chilukuri, H., Reddy, N. P., Pathapati, R. M., Manu, A. N., Jollu, S., & Shaik, A. B. (2014) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.127258 · Cited by 89
Dose- and Exposure-Response to Ketamine in Depression
Glue, P., Gulati, A., Nedelec, M. L., & Duffull, S. B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.11.031 · Cited by 84
Self-citationLong-Term Maintenance With Intramuscular Ketamine for Treatment-Resistant Bipolar II Depression
Cusin, C., Hilton, G. Q., Nierenberg, A. A., & D, M. F. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12020219 · Cited by 69
Gálvez, V., O’Keefe, E. J., Cotiga, L., Leyden, J., Harper, S., Glue, P., Mitchell, P. B., Somogyi, A. A., Delory, A., & Loo, C. K. A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.010 · Cited by 41
Self-citationSAFTEE: data system for side effect assessment scale.
Dj, C. (1986) · PubMed · Cited by 14
Research works printed but not linked: 1
- Sos P, 2013, Relationship of ketamine's antidepressant and psychomimetic effects in unipolar depression, Neuro Endocrinol Lett, 34, 287
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Given the absence of an adequately designed head-to-head trial, the relative efficacies of intranasal esketamine and intravenous racemic ketamine are not known (65).”
BackgroundSide-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Self-citationTargeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433
Metadata
- Authors
- Loo, C. K., Gálvez, V., O'Keefe, E., Mitchell, P. B., Hadzi‐Pavlovic, D., Leyden, J., Harper, S., Somogyi, A. A., Lai, R., Weickert, C. S., & Glue, P.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2016-03-30
- Volume
- 134
- Issue
- 1
- Pages
- 48-56
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2328324756
- Cited by
- 257
- References
- 24
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- Universitat de Barcelona
- University of New South Wales
- National Health and Medical Research Council (#1021970)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.